New Agents, New Options and Expanded Potential In Lipid Management: Integrating The Data Into Practice
WebcastFaculty
OVERVIEW
New Agents, New Options and Expanded Potential In Lipid Management: Integrating The Data Into Practice is organized by National Association for Continuing Education (NACE) and will be held during Aug 25, 2017 - Aug 24, 2018.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
This program will address the evidence behind primary and secondary prevention strategies for cardiovascular disease. The role and rationale for PCSK-9 inhibitors will be explored as well as current cardiovascular disease Quality Measures.
Conference Objectives are:
• Employ evidence based treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.
• Discuss ACC recommendations on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease.
• Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction.
• List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease.
Additional details will be posted as soon as they are available.
The target audience for this medical event is Primary Care Providers. This CME Conference has been approved for a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Description:
This program will address the evidence behind primary and secondary prevention strategies for cardiovascular disease. The role and rationale for PCSK-9 inhibitors will be explored as well as current cardiovascular disease Quality Measures.
Conference Objectives are:
• Employ evidence based treatment strategies for primary and secondary prevention of cardiovascular disease in high-risk patient populations.
• Discuss ACC recommendations on the role of non-statin therapies in the management of atherosclerotic cardiovascular disease.
• Explain the role of anti-PCSK9 monoclonal antibody therapy in LDL-C reduction to achieve cardiovascular risk reduction.
• List 2017 Quality Measures for the use of statin therapy for the prevention and treatment of cardiovascular disease.
Additional details will be posted as soon as they are available.
SPECIALITIES
CardiologyRELATED ONLINE COURSES
Quick Links